Eur J Cancer. 1992;28(2):399-403. doi: 10.1016/s0959-8049(05)80062-0.

Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas.

European journal of cancer (Oxford, England : 1990)

M B Phillips, C R Pinkerton

PMID: 1591053 DOI: 10.1016/s0959-8049(05)80062-0

Abstract

10 patients with refractory or relapsed soft tissue sarcoma were treated with weekly etoposide (150 mg/m2 on days 1, 2 and 3) and cisplatin (60 mg/m2 on day 2). Toxicity was mainly myelosuppression which resulted in deviation from planned weekly chemotherapy scheduling. With this rapid dose-delivery schedule the tolerated median dose intensities were 161 mg/m2 per week for etoposide and 49 mg/m2 per week for cisplatin. In 9 evaluable patients there were 7 responses, 2 complete and 5 partial, giving a response rate of 78% (confidence interval 51-100%). The combination of etoposide and cisplatin in this schedule produced a higher response rate than reported with previous schedules and is worthy of further evaluation.

Substances

• Etoposide
• Cisplatin

MeSH terms

• Adolescent
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use
• Child
• Child, Preschool
• Cisplatin / administration & dosage
• Cisplatin / adverse effects
• Etoposide / administration & dosage
• Etoposide / adverse effects
• Female
• Humans
• Infant
• Male
• Pilot Projects
• Sarcoma / drug therapy
• Soft Tissue Neoplasms / drug therapy

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't

LinkOut - more resources

• Full Text Sources
  • Elsevier Science
• Medical
  • MedlinePlus Health Information